Trends in Korean Medicine Utilization for Chronic Rhinosinusitis Using National Health Insurance Service Data (2012-2022)

Objectives: Chronic rhinosinusitis (CRS) is often treated with Korean medicine (KM), but comprehensive utilization data is lacking. This study aimed to analyze the patterns of KM use for CRS using National Health Insurance Service data from 2012 to 2022.Methods: We conducted a retrospective analysis of claims data for CRS patients (International Classification of Diseases code: J32) who visited KM institutions. We examined demographic characteristics, visiting patterns, medical costs, treatment modalities, and concurrent use of Western medicine.Results: Of 138,647 patients (52.2% male, mean age 23.8 years), 41.8% were under 10 years old. Annual patient numbers ranged from 14,595-17,242 (2012-2019), decreasing sharply from 2020. Average costs increased 5% annually. Acupuncture was the most common treatment (661,455, 50.5%). The most frequently prescribed insured herbal medicine was Hyeonggaeyeongyo-tang (48,494, 48.5%). Notably, 87.0% (120,610 patients) concurrently received Western medical treatment, indicating a prevalent integrative approach in CRS management. 77.8% received their initial diagnosis at Western institutions.Conclusion: This comprehensive analysis of KM utilization for CRS in Korea reveals significant patterns in patient demographics, treatment preferences, and integration with Western medicine. The high rate of concurrent KM and Western treatment highlights the integrative nature of CRS management in Korea, providing valuable insights for health policy and clinical practice.